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and net monetary benefit calculations. Sensitive variables include abiraterone
costs and neutropenia costs of mitozantrone. Even assuming most patients are
severely ill to match sites with sicker populations, the relative cost-effectiveness
does not change; abiraterone favored and cabazitaxel always above tolerable
thresholds. CONCLUSIONS: Abiraterone is the most cost effective given WTP of
$100,000. Despite slightly higher survival with cabazitaxel, it is never cost-effective
with high drug andneutropenia costs. Even for care siteswith relatively ill patients,
abiraterone remains cost-effective.
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ECONOMIC EVALUATION OF ANTITHROMBOTIC THERAPIES IN PATIENTS
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OBJECTIVES: Cancer is a risk factor to develop deep vein thrombosis (DVT), pulmo-
nary embolism (PE) or relapse of these conditions. Alternatives to oral anticoagu-
lants need to be evaluated. The objective of this study was to perform an economic
evaluation of anticoagulant therapies in adult patients with cancer (solid tumors),
from the Social SecurityMexican Institute (IMSS) perspective.METHODS:One-year
medical direct costs (2011 US$) and health consequences were estimated by a
Markov model (one-week cycles). Effectiveness measures were reduction in cases
of DVT and PE (per 1000 patients). A meta-analysis was performed to estimate
transition probabilities. Alternatives considered in the assessment were: warfarin
(5mg/day); dalteparin (not listed in Mexican formulary, 5000 IU/day); enoxaparin
(40 mg/day); nadroparin (5700 IU/day); unfractionated heparin (UFH) plus warfarin
(10000 IU/day5 mg/day) and no prophylaxis. Resource use and costs were ob-
tained through IMSS databases (dalteparin acquisition cost was provided by man-
ufacturer). Univariate sensitivity analysis was performed. Acceptability curves
were constructed. RESULTS: Estimated cases of DVT avoidedwere: warfarin 276 (CI
95% 271–281); dalteparin 47 (46–48); enoxaparin 107 (105–109); nadroparin 97 (95–
99); UFH 127 (124–130) and no prophylaxis 317 (310–323). Regarding PE prevention,
outcomes were: warfarin 116 (114–118); dalteparin 16 (16–16); enoxaparin 23 (23–
23); nadroparin 15 (15–15); UFH 26 (25–27) andno prophylaxis 61 (60– 62). Per patient
annual costs were: warfarin $1908.32 ($1851.38-$1918.42); dalteparin $2298.82
($2268.41-$2329.22); enoxaparin $3713.36 ($3634.27-$3792.46); nadroparin $2,648.14
($2603.54-$2692.76); UFH $1884.90 ($1851.38-$1918.42) and no prophylaxis $2667.81
($2619.18-$2716.42). For both DVT and PE, ICER=s of dalteparin, enoxaparin and
nadroparin were $1.72, $3.93; $10.70, $19.44, $4.15 and $7.35, respectively. In pre-
vention of bothDVTand PE, dalteparin ismore effective and less costly than enoxa-
parin, nadroparin and no prophylaxis. CONCLUSIONS: Dalteparin is a potential
cost-effective antithrombotic therapy in adult patients with cancer in Mexico.
PCN74
ECONOMIC EVALUATION OF EVEROLIMUS AS SECOND LINE TREATMENT IN
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OBJECTIVES: To evaluate the cost-effectiveness of Everolimus as second-line of
treatment compared with sorafenib in adult patients with metastatic renal cell
carcinoma, from the perspective of the Mexican Public Health Institution.
METHODS:We compare the results obtained in treating renal cancer patients with
either sorafenib or everolimus, previously treated with sunitinib in Mexico. We
developed amarkovmodel in a two-year period among three possible health states
(stable, progression and death). Overall survival and progression-free survivalwere
used as effectivenessmeasures and the sources of this informationwere published
articles. We considered the costs of drugs, best-supportive care and follow-up
(stable disease and progression); drug costs of everolimus and sorafenib only apply
to stable patients. The costs of medical resources correspond to the costs of med-
ical care in tertiary care systems. All costs were calculated in 2010 Mexican pesos.
An incremental analysis of cost and results in health was realized, to compare
everolimus and sorafenib. A sensitivity analysis was also accomplished (determin-
istic and probabilistic). The discount rate applied to costs and effectivenesswas 5%.
RESULTS: Patients with everolimus obtained more overall survival (14.37 vs. 7.73
months) and progression-free survival (4.83 vs. 3.88 months) than those that used
sorafenib. Everolimus resulted as the alternative with less average total cost than
sorafenib: $391,765.00 and $454,802.00 respectively. Everolimus is a dominant op-
tion compared with sorafenib. Sensitivity analysis showed robustness in the
results. CONCLUSIONS: Everolimus is the cheapest treatment option and saving of
resources, which significantly increases the survival of patients and provides lon-
ger progression-free and more overall survival versus sorafenib.
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OBJECTIVES:To evaluatewhether the use of bevacizumab in first line treatment for
patients with advanced ovarian cancer represents a cost-effective strategy for
health institutions in Mexico. METHODS: Ovarian Cancer is the sixth most com-
mon cancer and second gynecologic malignancy worldwide, with approximately
190,000 new cases per year. Ovarian cancer is considered highly lethal for their
growth characteristics, low symptoms and recurrence. A complete economic eval-
uation of cost-effectiveness was performed in womenwith ovarian cancer stage III
and IV, classified as high risk, taking carboplatin  paclitaxel (CP) and bevaci-
zumab carboplatinpaclitaxel (BCP) as comparators. The 1st cycle, carboplatin
paclitaxel are administered alone; from 2nd to 6th is added bevacizumab
(7.5 mg/kg). From cycle 7, all patients with no evidence of disease progression
received maintenance bevacizumab as monotherapy, giving a maximum of 18
cycles. The progression was emulated with aMarkovmodel considering the stages
of: progression free survival, progression and death in a 11.5 year time horizon.
Costs are expressed in US dollars. RESULTS: BCP gained more months with pro-
gression free survival compared with CP (16.77 vs. 14.40). BCP obtained 40.89
months of overall survival versus 31.17 with CP, generating a 36% increase in over-
all life expectancy. The Incremental Cost Effectiveness Ratio (ICER) for BCP is
$25,544 per year of additional life year gained with respect the use of CP. According
to the International Monetary Fund, the Gross Domestic Product (GDP) for Mexico
in 2011 was $9471. For a threshold of 3 times this value (3 GDP per capita: $28,413),
the use of BCP in advanced ovarian cancer would be cost-effective. CONCLUSIONS:
BCP is an alternative that substantially increases the patient overall survival ex-
pectancy. It also lies within the international cost-effectiveness threshold.
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OBJECTIVES:Assesswhether the use of Erlotinib as 1st line treatment inmetastatic
or advanced Non Small Cell Lung Cancer (NSCLC) patients with Epidermal Growth
Factor Receptor (EGFR) mutation positive, is a dominant alternative from the per-
spective of public health system in Mexico. METHODS: It was developed a cost-
utility analysis using a Markov model with monthly cycles stages: response to
treatment, stable disease, disease progression and death in a time horizon of 5
years. The costing method is the direct medical costs and the main outcome mea-
sures were QALY’s and total cost of treatment per patient. The drugs compared in
the study were Erlotinib, Gefitinib and chemotherapy with Gemcitabine plus Car-
boplatin. Costs are expressed in US dollars. RESULTS: Erlotinib was the alternative
that provided a greater number of QALY’s (1.49) compared with Gefitinib (1.32) and
chemotherapy with Carboplatin (1.07). Furthermore, treatment with Erlotinib was
the least expensive with a cost per patient of $51,249 on a horizon of 5 years while
the cost of Gefitinib was $ 53,817 per patient and the QT with Gemcitabine 
Carboplatin $53,258 per patient. This implies that the dominant treatment for
these patients (NSCLC and positive EGFR mutation) is Erlotinib with a cost-effec-
tiveness average of $34,456. The dominance results of treatment with Erlotinib
were consistent with sensitivity analysis, which provides robustness to the results.
CONCLUSIONS: Considering the average annual costs, Erlotinib represents savings
for the health sector from $402 (versus Gemcitabine  Carboplatin) to $514 (vs
Gefitinib) for each patient according to its comparator in 1 year. Therefore, under
the context of public health system inMexico, treatment with Erlotinib was shown
to be a cost-effective treatment and dominant over other treatment alternatives
considered in this study for patients with NSCLC and EGFR mutation.
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OBJECTIVES: The aim of this study is to assess efficiency of adding rituximab to
fludarabine and cyclophosphamide (R-FC versus FC) for the treatment of previ-
ously untreated chronic lymphocytic leukemia in Ukraine. METHODS: A cost-ef-
fectiveness analysis was performed from a health care perspective over a 20 year
horizon with 3% discounting rate. Markov model in Excel program (2007) with
cohort simulation was applied. Three-state model (no disease progress, relapse,
and death) was run using one month cycle time. The outcome data were retrieved
from a randomized controlled trial publication. One-way sensitivity analysis was
performed to assess robustness of the results. RESULTS: The incremental life ex-
pectancy increase was 3.27 months on R-FC in comparison to FC scheme. The
expected costs associated with FC scheme are equal to $28,105 and with FC-R
scheme to $41,850. R-FC was associated with incremental 1.3 quality-adjusted life-
years (QALYs) compared to FC and resulted in an incremental cost-effectiveness
ratio of $10,588 per QALY from health care perspective. Results were themost sensi-
tive tounitdrugcost for rituximab (costsdeviation$1.77-3.88permg).CONCLUSIONS:
The World Health Organization recommends to consider drugs cost-effective if their
incremental cost per QALY is less than 3 gross domestic product per capita in the
country ($6,700/per capita inUkraine). Under these recommendations, R-FC scheme is
seen as cost-effective in Ukrainian health-care setting.
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THE COST-EFFECTIVENESS OF TEMOZOLOMIDE IN THE ADJUVANT
TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA IN THE UNITED STATES
Messali A, Hay J, Villacorta R
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OBJECTIVES: The objective of this researchwas to determine the incremental cost-
effectiveness, from a US societal perspective, of adding temozolomide to the pre-
vious standard of care (radiotherapy only) for the adjuvant treatment of newly
diagnosed glioblastoma. METHODS: A Markov model with a one-month cycle
length and five-year time horizon was constructed in Microsoft Excel. All model
parameters were obtained from relevant peer-reviewed literature based on sys-
tematic review. Transition probabilities were calculated using survival data from
randomized controlled trials comparing temozolomide plus radiotherapy versus
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radiotherapy alone. Direct and indirect costs were derived from published peer-
reviewed literature or government data. Utilities were obtained from a previously
published cost-utility analysis of temozolomide and carmustine wafers in newly
diagnosed glioblatoma. Univariate and threshold sensitivity analyses were con-
ducted on all survival data, input costs, utilities, and other important parameters.
RESULTS: The addition of temozolomide to the standard radiotherapy regimen
was associated with a base-case incremental cost-effectiveness ratio of $154,933
per quality-adjusted life-year. This is considerably higher than the only other com-
parable estimate, which assumed the perspective of the UK National Health Ser-
vice and did not include indirect costs. The model was most sensitive to the utility
associated with the use of temozolomide during the maintenance phase of stable
disease treatment. CONCLUSIONS: The base-case incremental cost-effectiveness
ratio lies just beyond a willingness-to-pay threshold of $150,000 per quality-ad-
justed life-year. However, sensitivity analysis revealed numerous plausible scenar-
ios that produced lower estimates. Notably, a 10% increase in the utility associated
with stable disease treatment produced an estimate of $120,743 per quality-ad-
justed life-year. Given these results and the lack of alternative treatments for glio-
blastoma, we conclude that temozolomide’s use in this setting is not definitively
cost-effective. However, better estimates of relevant health state utilities could
greatly improve cost-effectiveness models for glioblastoma treatments.
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OBJECTIVES: To determine the costs, outcomes and level of cost-effectiveness
associated with HPV vaccination in urban China. METHODS: A Markov model of
HPV vaccination in urban China is used to follow hypothetical females from age 12
to age 92. The individuals in the model are assumed to be vaccinated at age 12 and
the rates of HPV infection, squamous intraepithelial lesions, cervical cancer and
death are measured on an annual basis for 80 years. All costs and outcomes are
discounted. RESULTS: In our base case analysis, the administration of HPV vaccine
could reduce cervical cancer rate by 65%. In ourmodel, HPV vaccination is found to
be cost-saving. The implementation of HPV vaccination results in an increase of 0.6
QALYs over the lifetime of each individual. The total lifetime discounted costs with
vaccination are $766 dollars per individual lower than the total costs without vac-
cination. Under all scenarios examined in our sensitivity analysis, the total costs
with vaccination are reduced when compared to current practice with an increase
in QALYs as well. CONCLUSIONS: Compared to current practice in China, which
does not include cervical cancer screening, HPV vaccination appears to be cost-
saving. China has a coverage rate of 95% for its childhood immunization program.
Incorporating HPV vaccination into this program could likely be done with a min-
imal amount of effort. Our results provide strong evidence for the implementation
of HPV vaccination programs in urban China.
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OBJECTIVES: The purpose of this research was to determine the cost-effectiveness
of sunitinib in terms of the RF health care system. In this research, the comparisons
of costs and effectiveness with patients treated by sunitinib, IFN-, sorafenib and
bevacizumab with IFN- were studied, based on the RF health care system
conditions.METHODS: In this Pharmacoeconomic research the cost-effectiveness
analysis (CEA) and cost-utility analysis (CUA) were studied. The results were esti-
mated in life years before the disease progression (PfLYs) and prolonged life years
(LYs)within CEA andquality-adjusted life-years (QALYs)within CUA. The results of
these analyses were illustrated in incremental cost-effectiveness rate (ICER) and
cost-utility rate (ICUR). The cost-utility analysis was chosen as the main analytical
method, because sunitinibwas supposed not only to affect survivability but quality
of life as well. RESULTS: The data of the research illustrates that sunitinib usage as
a first-line drug for mRCC patients provides a significant health improvement in
terms of PFS and OS, expressed in ICER index, equal to 3,742,060 rub and 955 451 for
a saved life year, and ICUR index, equal to 6,787,955 rub and 2,912,714 rub for QALY
in comparison with IFN- and sorafenib respectively. High values of these indexes
are mainly caused by high cost of sunitinib and relatively low cost of healthcare
resources in Russian Federation. In comparison with bevacizumab with IFN-,
sunitinib is dominant, providing better efficacy with lower cost. CONCLUSIONS:
These results suggest that sunitinib is a cost-effective alternative to sorafenib,
bevacizumab with IFN-, and sorafenib as a first-line treatment of mRCC.
PCN81
HEALTH RELATED QUALITY OF LIFE, DIRECT MEDICAL, NON-MEDICAL, AND
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OBJECTIVES: To evaluate the health-related quality of life (HRQOL) and to compare
direct medical, non-medical and indirect cost of stage III colorectal cancer(CRC)
patients receiving either capecitabine-based or 5-FU/LV-based adjuvant treat-
ments from societal perspective. METHODS: An observational follow-up study to
collect HRQOL and cost data from stage III CRC patients were conducted in 12
hospitals from 2008 to 2010. A total of 535 patients were invited to complete ques-
tionnaires during the study period: at study baseline (Q0), at 3 months after the
initial adjuvant treatment (Q3), and at 1 month after treatment had finished (Q7)
using the EORTC QLQ-C30 and QLQCR-38 questionnaires. Cost data were obtained
fromNational Health Insurance Research Database (NHIRD), patient questionnaire
(Q3) and productivities loss from Manpower Utilization Survey. 66% of patients
completed the questionnaire as per protocol and their data were the basis for
further analysis. Propensity score matching (PSM) method was used to reduce
selection bias and to avoid endogenous problems by matching variables, i.e. age,
gender, location of tumor, marital status, education, work and the number of co-
morbidities between two groups. After PSM, a total of 239 patients were analyzed.
RESULTS: In capecitabine-based treatment, Physical, Role, Emotional, Social,
Global Health status, Body Image, Future perspective Functioning, Fatigue, Pain,
Diarrhea, Stoma-related problem, and Weight loss Symptoms were all improved
from Q0 to Q3 and Q0 to Q7. In 5-FU/LV-based treatment, Physical, Role, Social,
Global health status Functioning, GI tract and Weight loss Symptoms also im-
proved. Total directmedical, direct non-medical, and indirect cost of capecitabine-
based and 5-FU/LV-based treatment were NT$29,452 (USD $982) and NT$55,200
(USD $1,840), respectively.CONCLUSIONS:This real-life study shows that adjuvant
chemotherapy has no negative impact on HRQOL during study period. Capecit-
abine-based treatment performs better in most functioning aspects of HRQOL and
is cost-saving in direct and indirect resources utilization from societal perspective.
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Yagudina R, Kulikov A, Misikova B
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
OBJECTIVES: To assess the cost-effectivness of lenalidomide in treatment of the
second and third lines of multiple myeloma in the Russian Federation.METHODS:
We developed an economic model of multiple myeloma disease to calculate the
cost of diagnosis and treatment of second and third-line therapy of lenalidomide
and bortezomib. The efficacy of drugs (time to progression- TTP)was obtained from
clinical trials: MM - 009/-010 for lenalidomide; APEX for bortezomib. TTP for lena-
lidomide was 21.2 months and for bortezomib - 16.4 months. Medical care costs
were estimated from the standard of multiple myeloma treatment, which was
developed and published by Ministry of public health. RESULTS: A CER of lenalido-
mide in the second line therapy was 468,110,84 RUB (11,529,82 €) which is lower
then use of bortezomib in the second line therapy 605 118,89 RUB (14,904,4 €).
CONCLUSIONS: Application of lenalidomide in second-line therapy of multiple
myeloma is dominated alternative of treatment.
PCN83
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OBJECTIVES: Formany years, the backbone of cancer treatment has been the use of
cytotoxic agents. There has been an emergence of new drugs, however, that are
more specific to the target. Some of these agents have resulted in a prolongation of
survival and even clinical cures in some cancers. In order to compare and contrast
the costs and benefits of these new drug therapies, a descriptive evaluation across
seven major tumour types was undertaken. METHODS: A literature search was
conducted from 2000 to 2011 to identify randomized trials of novel therapies in
breast, lung, colorectal, kidney, lymphoma, multiple myeloma and chronic my-
elogenous leukemia. Clinical outcomes in terms of progression free (PFS) and over-
all survival (OS) benefit were extracted. Economic data in terms of cost per month
of therapy was obtained from a U.S. cancer clinic. RESULTS: Approximately 22
novel therapies were approved across the seven cancers. Four of the 22 (18%) were
used with a curative intent while the remainder were used in the palliative setting
(n18). Ten of these 18 (56%) latter agents also demonstrated an OS benefit. The
median month cost for novel therapies used with a curative intent and those with
a survival benefit in the palliative setting were $5450 and $6450 respectively. In
contrast, the median monthly cost for drugs that did not offer either of these
benefits was $7900. Of the agents identified, imatinib, lenalidomide, rituximab and
trastuzumab provided the greatest magnitude of benefit for both PFS and OS and
would be considered major clinical advances. CONCLUSIONS: Approximately 64%
of novel drugs approved over the past 11 years are used with a curative intent or
provide a survival benefit in the palliative care setting. Themonthly cost for agents
not providing these benefits, however,was higher, indicating a disconnect between
efficacy and cost.
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ECONOMIC EVALUATION OF THE USE OF CAPECITABINE AS FIRST-LINE
TREATMENT OF METASTATIC COLORECTAL CANCER IN MEXICO
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OBJECTIVES: To identify which is the chemotherapy scheme alternative that
minimizes costs in the 1st line treatment of Metastatic Colorectal Cancer
(mCRC) in Mexico.METHODS: Costminimization comparing different chemother-
apy schemes for mCRC: XELOX (CapecitabineOxaliplatin), FOLFOX-4
(OxaliplatinFluorouracilfolinic acid), FOLFOX-6 (Oxaliplatin Fluorouracil fo-
linic acid) and FOLFIRI (IrinotecanFluorouracilfolinic acid). It was performed a
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